FDA Rare Disease Hub, Draft Guidance, and Regulatory Updates for 2026
FDA released its 2026 Rare Disease Hub Strategic Agenda and a draft guidance on 3-year New Clinical Investigation Exclusivity. The agency also outlined new pathways including the plausible mechanism pathway and Rare Disease Evidence Principles to accelerate treatments for rare diseases.
The U.S. Food and Drug Administration (FDA) has released its 2026 Strategic Agenda for the Rare Disease Hub, established in July 2024 as a point of collaboration between the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) with the goal of improving outcomes for patients. The hub focuses on products intended for smaller populations or for diseases where the natural history is variable and not fully understood.
The agenda highlights three accomplishments from 2025: the Rare Disease Innovation, Science, and Exploration (RISE) workshop series, which focuses on issues common to therapy development for multiple rare diseases; the Rare Disease Policy and Portfolio Council (RDPPC), a cross-Center collaborative body that meets monthly to convene senior medical product leadership and subject matter experts from CBER and CDER; and the creation of a public-facing email address and website to promote contact with the rare disease community.
Looking ahead, the FDA will prioritize advancing regulatory science of rare disease therapies, including enhancing opportunities for novel endpoints, biomarker development and assays, innovative trial design, real-world evidence (RWE), and statistical methods. The next RISE workshop is scheduled for March 30, 2026. The agency will also strengthen coordination between medical product Centers, including alignment on review standards and decision-making, and create a centralized point of contact for external partners.
In November 2025, FDA leaders published an article in the New England Journal of Medicine outlining a new "plausible mechanism pathway," under which a drug or biologic manufacturer may be able to obtain FDA marketing authorization for products targeting specific, well-understood genetic abnormalities. This approach is intended to address areas of unmet need where traditional trials would be infeasible. A draft guidance document for this pathway was recently circulated to the White House for review.
In September 2025, the FDA announced its "Rare Disease Evidence Principles" (RDEP), under which eligible drugs and biologics for ultra-rare diseases caused by known genetic defects will receive assurance of FDA consideration of additional supportive data that may be used to meet regulatory approval standards. For programs meeting eligibility requirements, the FDA said it will offer an additional meeting with the appropriate review team.
In March 2026, CDER issued a draft guidance for industry titled "New Clinical Investigation Exclusivity (3 years exclusivity) for drug products: Questions and answers." The guidance seeks to provide additional clarification regarding the statutory and regulatory criteria for eligibility for 3-year exclusivity, also known as New Clinical Investigation Exclusivity, and outlines recommendations on the content and format of requests submitted by applicants seeking this protection.
The FDA recognizes several types of exclusivities, including Orphan Drug Exclusivity (7 years), New Chemical Entity Exclusivity (5 years), Generating Antibiotic Incentives Now (GAIN) Exclusivity (5 years added to certain exclusivities), Pediatric Exclusivity (6 months added to existing patents or regulatory exclusivities), Patent Challenge Exclusivity (180 days), and Competitive Generic Therapy Exclusivity (180 days). The 3-year exclusivity provision primarily rewards sponsors for conducting additional clinical investigations that support new uses, new dosing regimens, or other clinically meaningful changes to already approved drug products.
An application may qualify for 3-year exclusivity if it is a New Drug Application (NDA) submitted under section 505(b)(1) or 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or a supplement to an existing NDA. The application must contain reports of "new clinical investigations," other than simple bioavailability studies, that are essential to the approval and were conducted or sponsored by the applicant. The FDA clarifies that an investigation is not considered essential simply because the applicant conducted the study — the determination depends on whether no other available data could support the approval.
The request for 3-year exclusivity must be included in the Module 1 folder of the NDA submission. Once granted, the exclusivity information is reflected in the FDA's Orange Book, which serves as the official and publicly accessible source of information regarding exclusivity periods for approved drug products.